ArticleInfection and immunity2004
Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells.
Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- DcR3 Suppresses Lipopolysaccharide-Induced Aggresome-like Structures in Macrophages via Inhibition of Reactive Oxygen Species and p38 MAPK.International journal of molecular sciences · 2026Article
- Decoy receptor 3 as a prognostic biomarker for sepsis and septic shock according to the Sepsis-3 definitions.Frontiers in cellular and infection microbiology · 2025Article
- Correlation of Serum Decoy Receptor 3 and Interleukin-6 with Severity of Coronary Artery Diseases in Male Acute Myocardial Infarction Patients.Acta bio-medica : Atenei Parmensis · 2021Article
- Article
- Decoy receptor-3 regulates inflammation and apoptosis via PI3K/AKT signaling pathway in coronary heart disease.Experimental and therapeutic medicine · 2019Article
- Increased circulating levels of tumor necrosis factor-like cytokine 1A and decoy receptor 3 correlate with SYNTAX score in patients undergoing coronary surgery.The Journal of international medical research · 2018Article
- DcR3, a new biomarker for sepsis, correlates with infection severity and procalcitonin.Oncotarget · 2018Article
- Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions.Journal of biomedical science · 2017Review
- Predictive value of decoy receptor 3 in postoperative nosocomial bacterial meningitis.International journal of molecular sciences · 2014Article
- The role of TL1A and DR3 in autoimmune and inflammatory diseases.Mediators of inflammation · 2013Review
- Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis.Diagnostic microbiology and infectious disease · 2012Article
- Decoy receptor 3, a novel inflammatory marker, and mortality in hemodialysis patients.Clinical journal of the American Society of Nephrology : CJASN · 2012Article
- Programmed cell death of dendritic cells in immune regulation.Immunological reviews · 2010Review
- Significance of increased expression of decoy receptor 3 in chronic liver disease.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2009Article
- Immunoregulation by tumor necrosis factor superfamily member LIGHT.Immunological reviews · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor (TNF) receptor 6/decoy receptor 3 (TR6/DcR3) is an antiapoptosis soluble receptor of the TNF family produced by tumor cells. In this study, TR6 expression in human immune cells was investigated. TR6 mRNA and protein were detectable in selected antigen-presenting cells. Monocytes and myeloid-derived dendritic cells (MDC) released the protein exclusively following stimulation of Toll-like receptor 2 (TLR2) and TLR4 by gram-positive and gram-negative bacterial antigens. Plasmacytoid dendritic cells, activated by bacterial antigens via TLR9 or by viral infection, did not produce the protein. Similarly, activated T cells did not release TR6. The release of TR6 by MDC was dependent on the activation of p42/p44 mitogen-activated protein kinases, Src-like protein tyrosine kinases, and phosphatidylinositol 3-kinase, signaling pathways important for MDC maturation and survival. In agreement with the in vitro data, TR6 levels in serum were significantly elevated in patients with bacterial infections. Overall, these data suggest a novel role for TR6 in immune responses to bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.